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Introduction DMD # 67447 8 added, and the mixture was centrifuged (2000 x g, 5 min at room temperature). The concentration of midazolam utilized in the assay approximated its K M value that had been previously determined, and the incubation time was selected based on previous determinations of reaction velocity linearity (Walsky and Obach, 2004) . The supernatant was mixed with an equal volume of water containing 0.2% formic acid then analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) for 1'-hydroxymidazolam using validated bioanalytical conditions established previously (Walsky and Obach, 2004) . Formation of 1'-hydroxymidazolam was quantitated using Analyst version 1.6 (Sciex, Framingham, MA).
Standard curve regression used linear regression with 1/x 2 weighting. Resulting 1'-hydroxymidazolam concentrations were normalized to concentrations measured in solvent controls. IC 50 was calculated with GraphPad version 6 (GraphPad Software, San Diego, CA) using the log(inhibitor) versus normalized response equation assuming a Hill slope of -1.0; automatic outlier determination was enabled and no curve fitting restraints were included.
To examine the ability of FA to act as a time-and concentration-dependent inhibitor of human CYP3A4, incubations were carried out with seven FA concentrations in duplicate.
Inactivation kinetic experiments have been described previously (Ghanbari et al., 2006; Obach et al., 2007; Polasek and Miners, 2007) . Human liver microsomes (0.3 mg/ml), MgCl 2 (3.3 mM),
and NADPH (1.3 mM) in potassium phosphate buffer (100 mM, pH 7.4) were pre-warmed in a dry heat bath at 37 °C for 5 minutes. Incubation was initiated with the addition of inhibitor or control solvent (2 µl, final incubation volume 0.2 ml). Inhibitor stock solutions were prepared in water at 100-times the final incubation concentration. Inhibitor concentrations, between 3-500 µM, were approximately evenly spaced after applying a log transformation. At several time DMD # 67447 1 0
inhibitor at the highest concentration tested in the activity incubation and indicated that FA did not suppress the 1'-hydroxymidazolam signal. The natural log (ln) of the percentage remaining activity was plotted against the preincubation time. The slope (-k obs ) of each line was then calculated for the linear portion of the curve using GraphPad Prism v6 software. The automatic outlier elimination function was enabled. The details of the statistical TDI data analysis have been described by Yates et al. (2012) with 0.2 ml ice-cold uptake buffer. The cells were then lysed with 100 µl of ice-cold methanol containing indomethacin (0.1 μg/ml) as the internal standard. The lysate was mixed with 100 μl water, vigorously vortex-mixed, and a 10 μl aliquot was injected onto an LC-MS/MS system. LC-MS/MS analysis was performed on an AB Sciex Triple Quad™ 4000 mass spectrometer (TurboIonSpray™ interface) with Shimadzu LC-20AD Prominence HPLC pumps (Shimadzu Scientific Instruments, Columbia, MD) and a CTC Analytics Leap Technologies HTC PAL autosampler. The HPLC flow rate was 0.3 ml/min. A gradient method was used with samples loaded onto a Phenomenex XB-C18 30 × 2.1 mm column (Phenomenex, Torrence, CA) using 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). Samples were eluted using a gradient that began with 10% B for the first 0.5 min, which was then linearly increased to 90% B at 1.25 min and held at this mixture for 0. Samples were taken from the donor chambers before and after incubation to determine the initial concentration (C 0 ) (5) (6) (7) (8) (9) (10) . An internal standard solution, 120 and 180 µl of 0.5 µg/ml internal standard (CP-628374, MW = 687.04) in 100% methanol, was added to the receiver and donor samples, respectively. The samples were analyzed by LC-MS/MS to determine the peak area for digoxin, pitavastatin and the internal standard. LC-MS/MS protocols for the analysis of digoxin and pitavastatin have been published (Hirano et al., 2005; Yao et al., 2003) . All incubations assessing the inhibitory effect of FA on MDR1 and BCRP were conducted in triplicate.
Estimation of Kinetic Constants for
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Apparent permeability values (P app ) were calculated according to the following equation:
Where dx is the amount of compound in the receiver compartment, dt is the incubation time, and A is the area of the filter of the transwell plate.
Efflux ratio (ER) values were calculated according to the following equation:
Percent efflux values were calculated according to the following equations:
From the percent efflux ratios of probe, IC 50 values for inhibition of efflux of probe substrates were determined with GraphPad Prism 6 using the following equation as described by Rautio et al (2006) . Prediction of DDI potential of FA using a Static (R) Model. The magnitude of DDI arising via inhibition for OATP1B1-mediated hepatic uptake (R value) by FA was calculated using the equation (Giacomini et al., 2013; Tweedie et al., 2013) :
Where K i would represent the inhibition constant for OATP1B1 by FA and I in,max,u represents the estimated maximum unbound FA concentration at the inlet to the liver and is defined as follows (Ito et al., 2002) . The magnitude of clinical DDI (calculation of R value) for inhibition of OATP1B1-mediated hepatic was estimated using a static model (equations 7-9) depicted in the Materials and Methods section. The total FA C max at the clinically efficacious dose (500 mg, three times daily)
This article has not been copyedited and formatted. The final version may differ from this version. (2011), was 2 h, resulting in k a of 1.7 h -1 , and F a and F g were set to unity. As such, the assumptions around F a and F g in the estimation of I in,max,u are reasonable considering that the pharmacokinetics of FA in humans are prototypic of carboxylic acid-based drugs with a low plasma clearance (0.3 ml/min/kg) and an oral bioavailability > 90% (Turnidge, 1999) . The corresponding I in,max,u and R values were ~ 1.4-2.5
μM and 1.9-2.6, respectively, utilizing a OATP1B1 inhibition K i value equal to its IC 50 value of 1.59 μM, which is a reasonable assumption (Cheng and Prusoff, 1973) considering that the human OATP inhibition studies utilized a rosuvastatin substrate concentration approximately 4-fold below its previously estimated K m value of 20 μM (Pfizer data on file). The K M value for rosuvastatin uptake in HEK-OATP1B1 cells, generated in our laboratory, is in good agreement with a previously reported value of ~ 13 μM (van de Steeg et al, 2013) . Suffice to say, our prediction of K i (equal to the OATP1B1 IC 50 value) also assumes that OATP1B1 inhibition by FA is competitive in nature. This is due to the fact that our OATP inhibition studies instituted a preincubation step with FA to capture any time-dependent OATP inhibitory component like the one been noted with cyclosporine (Amundsen et al., 2010; Shitara et al., 2012; Gertz et al., 2013) .
DDI Study in Rats.
To assess potential DDI between rosuvastatin and FA, a single-dose oral DDI study was conducted with male Wistar-Han rats. The plasma concentration-time profile of rosuvastatin after administration of rosuvastatin alone or in combination with FA is presented in rosuvastatin (3 mg/kg), resulted in a significant increase (~ 25-fold) in rosuvastatin systemic exposure (i.e., AUC (0-tlast) of 15 ± 5.8 versus 369 ± 90 ng.h/ml, respectively) ( Table 1) .
Treatment with FA also caused a substantial increase (~ 19-fold) in the C max (from 7.63 ± 3.99 to 147 ± 54.5 ng/ml). The t 1/2 of rosuvastatin was similar between the two treatments (i.e., 2.3 versus 3.5 hour). Following oral administration at 250 mg/kg (see Figure 5 , inset), systemic exposure of FA as assessed from AUC (0-tlast) was 15167 ng.h/ml. The corresponding C max was 5233 ng/ml and occurred at a T max = 1.6 h (k a = 0.036 min -1 ), which is longer than the previously 
Discussion
Contrary to speculations in the product label, FA was a weak reversible and weak timedependent inhibitor of CYP3A4 activity in human liver microsomes. Although systematic clinical DDI studies between FA and drugs metabolized by CYP3A4 have not been performed, our data suggests that muscular toxicity of statins is unlikely to be mediated via inhibitory effects of FA on hepatic CYP3A4 activity, especially in light of the relatively low unbound maximal systemic concentrations (1.16-2.32 μM) at its efficacious dosing regimen. Rather, our present work demonstrates that musculoskeletal toxicity may arise through FA's inhibitory effects on OATP in the liver, which could inhibit hepatic uptake and lead to excessive blood and tissue levels of statins in the clinic in a manner similar to that noted with other OATP inhibitors (Moβhammer et al., 2014) . This hypothesis is attractive because it collectively accounts for the This article has not been copyedited and formatted. The final version may differ from this version. rhabdomyolysis noted with all statins including rosuvastatin, which is not metabolized by CYP3A4 (Martin et al., 2003) , and as such, is not prone to DDIs via CYP inhibition (Neuvonen, 2010 Efflux transporters MDR1 and BCRP are expressed at the canalicular membrane, and are involved in the biliary efflux of statins (Li et al., 2011) . These transporters are also expressed on the apical membrane of the enterocytes and are known to limit the intestinal absorption of value of 24 μM due to a longer T max of 1.6 h (instead of the reported value of 0.25 h).
Nevertheless, the I in,max,u value is within the range of Oatp1a2/1b4 IC 50 values, and since Oatpmediated hepatic uptake is the rate-limiting step in rosuvastatin clearance in rats (as is the case in humans), it is tempting to speculate that the origins of the DDI between rosuvastatin and FA are atleast partially mediated through inhibition of rosuvastatin uptake by FA. In rats, Oatpmediated uptake clearance of rosuvastatin is limited by hepatic blood flow (He et al., 2014) , and thus a large AUC ratio (observed AUC ratio in our present study ~ 25) is expected upon complete inhibition of transporter-mediated uptake. In the case of humans, the hepatic extraction of rosuvastatin is ~ 60% of hepatic blood flow (Martin et al., 2003) suggesting that the magnitude of rosuvastatin-FA interaction in human could be relatively smaller than that observed in our in vivo rat DDI study.
Against this backdrop, the synergistic contribution of FA metabolites towards inhibition of hepatobiliary transporters in humans and rodents cannot be excluded. Examination of the excretion routes in humans reveals minimal biliary, fecal, and renal excretion of unchanged FA (Godtfredsen and Vangedal, 1966; Singlas et al., 1988; Reeves, 1987) suggesting that metabolism is the principal elimination mechanism of FA in humans. Preliminary metabolite identification studies (Godtfredsen and Vangedal, 1966) Finally, our present findings also raise an intriguing possibility that the clinical cases of hyperbilirubinemia/jaundice noted with FA use (Humble et al., 1980; Kutty et al., 1987; Haddad et al., 1993) 
